View Older Stories View More Recent Stories
-
Stocks expected to have increasing option volume: PFE AMZN AVGO DAL UAL AAL LUV SAVE JBLU ALGT HA AA ENV
-
Pfizer jumps as it advances development of its weight-loss pill Danuglipron
-
Novo Nordisk (NVO), Others Decline After Pfizer (PFE) Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
-
Pfizer (PFE) Advances Development of Danuglipron
-
Evotec SE (EVO) and Pfizer Collaborate to Advance Drug Discovery in France
-
Midday movers: Nvidia, Eli Lilly rise; BP, Novo Nordisk fall
-
Intel, Nvidia, Eli Lilly rise premarket; BP, Novo Nordisk fall
-
Pfizer (PFE) Announces Departure ofe Chief Scientific Officer and President Mikael Dolsten
-
Correct: FDA Evaluation Of Dolutegravir Risk Reported In 2018
-
Pfizer (PFE) option IV flat into 2024 elections
-
Pfizer (PFE) Appoints Cyrus Taraporevala to its Board
-
Pfizer (PFE), BioNTech (BNTX) Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
-
Pfizer (PFE) Declares $0.42 Quarterly Dividend; 6.1% Yield
-
Sarepta Therapeutics gains as Pfizer failure removes overhang
-
Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
After-hours movers: Broadcom, Dave & Buster's, Oxford Industries, and more
-
Sarepta Therapeutics (SRPT) Climbs After Pfizer (PFE) Study in DMD Fails
-
Pfizer (PFE) Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys
-
Moderna (MRNA) price target raised at Oppenheimer after RSV vaccine approval
-
Popular stocks with increasing volume: CRWD TSM WMT SOFI PFE LVS MBLY MU LUV
-
Jefferies Reiterates Buy Rating on Pfizer (PFE)
